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 Intracardiac serum galectin (Gal)-3 levels
are shown to be greater in patients with
persistent than paroxysmal atrial
ﬁbrillation (AF), and the Gal-3 level was
an independent predictor of AF
recurrences after a single ablation
procedure.
 In a sheep model, the Gal-3 inhibitor GM-
CT-01 (GMCT) reduced atrial ﬁbroblast
proliferation in vitro.
 GMCT mitigated atrial dilation, myocyte
hypertrophy, ﬁbrosis, and the expected
increase in DF during transition to
persistent AF.
 GMCT-treated sheep hearts had longer
action potential durations, and fewer
rotors and wavebreaks during AF than
control.
 GMCT increased the number of sponta-
neous AF terminations and reduced
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AF = atrial ﬁbrillation
APD90 = action potential
duration at 90% repolarization
BNP = brain natriuretic peptide
CRP = C-reactive protein
CS = coronary sinus
DF = dominant frequency
Gal = galectin
GMCT = GM-CT-01
LA = left atrium
PLA = posterior left atrium
SMA = smooth muscle actin
TGF = transforming growt
factor
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reAtrial ﬁbrillation (AF) usually starts as paroxysmal but can evolve relentlessly to the persistent and perma-
nent forms. However, the mechanisms governing such a transition are unknown. The authors show that
intracardiac serum levels of galectin (Gal)-3 are greater in patients with persistent than paroxysmal AF and
that Gal-3 independently predicts atrial tachyarrhythmia recurrences after a single ablation procedure. Using
a sheep model of persistent AF the authors further demonstrate that upstream therapy targeting Gal-3
diminishes both electrical remodeling and ﬁbrosis by impairing transforming growth factor beta–mediated
signaling and reducing myoﬁbroblast activation. Accordingly, Gal-3 inhibition therapy increases the proba-
bility of AF termination and reduces the overall burden of AF. Therefore the authors postulate that Gal-3
inhibition is a potential new upstream therapy to prevent AF progression. (J Am Coll Cardiol Basic Trans Science
2016;1:143–54) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology
Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).A trial ﬁbrosis is a hallmark of atrial ﬁbrillation(AF)–induced structural remodeling andplays an important role in AF perpetuation
(1). The b-galactoside binding lectin galectin (Gal)-3
is highly expressed in ﬁbrotic tissues (2–4); it associ-
ates with cardiac ﬁbrosis during heart failure (5) and
increases risk for heart failure and mortality (6). Gal-
3 contains a carbohydrate-binding domain linked by
an amino-terminal nonlectin region that favors for-
mation of Gal-3 pentamers (7). Gal-3 pentamers bind
to transforming growth factor (TGF)-b receptors
causing cell surface retention and internalization of
the receptors, which is important for mediating dura-
tion and directionality of signaling through Smad and
Akt proteins (8,9).
Recent studies demonstrated that serum Gal-3 is
elevated in AF patients with preserved left ventricu-
lar function (10). Contrastingly, others suggested that
elevation of Gal-3 was driven by cardiometabolic
comorbidities and not heart rhythm (11). In the
present study, we endeavored to determine whether
Gal-3 mediates structural and electrical remodeling
during AF progression. We conducted a blinded
saline-controlled study in atrially tachypaced sheep
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GM-CT-01 (GMCT), a galactomannan that inhibits
Gal-3 by binding to its carbohydrate-binding
domain (4). Our results suggest a role for Gal-3 in
atrial remodeling of persistent AF in humans, and
provide compelling experimental evidence that Gal-3
inhibition reduces AF burden by mitigating structural
and electrical remodeling.
METHODS
An expanded methods section is available in the
Supplemental Appendix.
CLINICAL STUDY PROTOCOL AND FOLLOW-UP. All
clinical procedures were approved by the Institu-
tional Review Board of the University of Michigan. An
electrophysiologic study was performed under
conscious sedation. Blood samples were collected
from the coronary sinus (CS) and left atrium (LA) for
measurement of Gal-3, C-reactive protein (CRP), and
brain natriuretic peptide (BNP). Mean AF cycle length
was measured on lead V1 and correlated with Gal-3
levels in both CS and LA. Catheter navigation, map-
ping and ablation were performed with the guidancelth System – Peking University Health Science Center
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145of an electroanatomical mapping system (CARTO-3,
Biosense Webster, Inc., South Diamond Bar,
California). The ablation strategy for AF involved
antral pulmonary vein isolation followed by ablation
of complex fractionated atrial electrograms, when
needed. Patients were seen in an outpatient clinic 3
months after the procedure and every 6 months
thereafter. Any atrial arrhythmias (tachycardia,
ﬂutter, or ﬁbrillation) lasting >30 s, 3 months after
the ablation indicated recurrence.
PROTOCOL FOR BLINDED SALINE-CONTROLLED
SHEEP TRIAL. All animal procedures were approved
by the University of Michigan Committee on Use and
Care of Animals and complied with National In-
stitutes of Health Guidelines. Twenty-four male
sheep (z40 kg) underwent subcutaneous pacemaker
implantation with an atrial lead attached to the right
atrial appendage. After 1 month recovery, sheep were
randomized to: 1) saline-treated AF (control);
2) GMCT-treated AF; or 3) sham-operated non-AF
groups. Intermittent tachypacing was initiated in the
AF animals with automatic mode switch enabled for
tachypacing only during detected episodes of sinus
rhythm. Device onboard memory was used to store
number, duration and timing of AF episodes, as well
as intracardiac electrograms for post-acquisition
analysis. After 35 days of self-sustained AF without
pacing, animals were euthanized and hearts were
removed for either ex vivo optical mapping, or
patch-clamping and molecular biology experiments.
Investigators were blinded to treatment until the end
of follow-up.
RESULTS
Fifty-ﬁve patients (Supplemental Table 1) who un-
derwent de novo radiofrequency ablation to elimi-
nate paroxysmal (n ¼ 29) or persistent AF (n ¼ 26)
were investigated. Serum Gal-3, CRP, and BNP were
measured in blood samples from the LA cavity and CS
prior to ablation (Figure 1A). Gal-3 levels were greater
in patients with persistent than paroxysmal AF, but
CRP and BNP levels were not signiﬁcantly different.
Notably, mean AF cycle length in V1 was inversely
related to Gal-3 serum levels in both LA and CS
(Figure 1B), and LA volume index correlated posi-
tively with Gal-3 serum levels in both LA and CS
(Figure 1C).
During 12 months of follow-up after a single radio-
frequency ablation, 24 of 29 patients with paroxysmal
AF and 15 of 26 patients with persistent AF were in
sinus rhythm. Gal-3 levels in CS and LA were higher in
patients with than without recurrent atrial arrhyth-
mias (CS: 14.9  0.7 ng/ml vs. 12.1  0.6 ng/ml,p ¼ 0.006; and LA: 14.1  0.7 ng/ml vs. 11.9 
0.6 ng/ml, p ¼ 0.027). Multivariate analysis revealed
Gal-3 levels in CS to be the only independent predictor
of recurrent atrial arrhythmias after a single radio-
frequency ablation among biomarkers tested
(odds ratio: 1.20; 95% conﬁdence interval; 1.01 to 1.45;
p ¼ 0.049) (Supplemental Table 2). Receiver-
operating characteristic curve analysis demonstrated
that a Gal-3 level >13.05 ng/ml in CS and >11.9 ng/ml
in LA (Figure 1D) was predictive of recurrences after a
single ablation with 76% sensitivity and 71% speci-
ﬁcity, and 81% sensitivity and 65% speciﬁcity,
respectively.
PROLIFERATION OF SHEEP ATRIAL MYOFIBROBLASTS
IN VITRO. We conducted in vitro experiments to
investigate whether Gal-3-regulated proﬁbrotic
pathways mediate atrial ﬁbrosis in AF through acti-
vation of ﬁbroblasts. The level of transcript of LGALS3
coding for Gal-3 was similar in sheep lung and LA
ﬁbroblasts, and Western blot analysis conﬁrmed Gal-3
protein in atrial myoﬁbroblasts (data not shown). In
cultured sheep atrial myoﬁbroblasts, GMCT inhibited
Gal-3-induced enhancement of migration and wound
healing, a measure of myoﬁbroblast activation
(Supplemental Figure 1). Treatment with either re-
combinant human Gal-3 or TGF-b1 increased the
number of atrial myoﬁbroblasts; and the effects were
blocked by GMCT (Figures 2A and 2B). Gal-3–induced
proliferation was fully blocked by TGF-b1 neutralizing
antibody (Figure 2C). GMCT can also bind to Gal-1 (13),
suggesting that Gal-1 might mediate the preventive
effects of GMCT on ﬁbroblast proliferation; however,
ﬁbroblast proliferation assays demonstrated that
Gal-1 increased ﬁbroblast proliferation but GMCT did
not inhibit the Gal-1 effects (Figure 2D).
STRUCTURAL REMODELING DURING AF PROGRESSION
IN SHEEP. We then conducted a blinded, placebo-
controlled study in atrially tachypaced sheep.
Twenty-four sheep were randomized to intravenous
GMCT treatment (12 mg/kg; n ¼ 10) twice per week,
intravenous saline treatment (n ¼ 10) twice per week
or sham (n ¼ 4). We deﬁned 4 time points from the
start of tachypacing: 1) ﬁrst AF episode (1st-AF);
2) ﬁrst 1-day-long AF episode (1d-AF); 3) ﬁrst contin-
uous 7-day stretch of persistent AF (7d-PeAF); and
4) ﬁrst continuous 35-day stretch of persistent AF
(35d-PeAF).
Body weight gain was comparable between GMCT
and saline-treated groups. No animals developed
heart failure (Supplemental Table 3). The AF-
associated LA dilation was signiﬁcantly attenuated
in GMCT-treated compared to saline-treated animals
(Figure 3A), which matched directly measured atrial
FIGURE 1 Serum Gal-3 in AF Patients and Receiver-Operator Characteristic Curve
(A) Fibrosis and inﬂammation biomarkers in patients with paroxysmal and persistent atrial
ﬁbrillation (AF). (B) Mean AF cycle length in lead V1 is inversely related to galectin (Gal)-3
in both coronary sinus (CS) and left atrium (LA). (C) LA volume index is related to Gal-3 in
both LA and CS. Receiver-operator characteristic curve of Gal-3 levels in both CS (D)
and LA (E) differentiating patients with and without recurrent atrial arrhythmias after a
single ablation procedure. AUC ¼ area under the curve; CI ¼ conﬁdence interval; CRP ¼
C-reactive protein. *p < 0.05.
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146areas (Figure 3B, Supplemental Figure 2). At the
myocyte level, cell areas from the saline-treated
group were signiﬁcantly increased over sham, but
increases were attenuated by GMCT (Figure 3C).
Procollagen type III N-terminal peptide, a serum
marker for collagen synthesis (14), increased pro-
gressively in saline-treated animals, but signiﬁcantly
decreased from baseline with GMCT treatment
(Figure 4A). In addition, at 35d-PeAF, tissue levels of
Gal-3 and TGF-b1 proteins in LA were signiﬁcantly
increased but Gal-1 was decreased; those effects were
not affected by GMCT (Figure 4B). In keeping with the
procollagen III N-terminal propeptide data, ﬁbrotic
areas in LA and posterior LA (PLA) and protein levels
of a-smooth muscle actin (SMA) from the LA and
PLA were signiﬁcantly lower in GMCT-treated than
saline-treated group, and were similar to sham
(Figures 4C and 4D). GMCT treatment signiﬁcantly
inhibited TGF-b1-mediated signaling pathways as
indicated by a decrease in activation of Smad2/3
proteins (Figure 4E).
IONIC AND MOLECULAR MECHANISMS OF ELECTRICAL
REMODELING. As AF progressed, atrial dominant
frequency (DF) increased faster in saline-treated
than GMCT-treated groups, and DFs were signiﬁ-
cantly higher at 35d-PeAF in saline-treated than
GMCT-treated animals (Figure 5A). Optical mapping
was conducted at ﬁnal evaluation (n ¼ 12). Regional
maximal DF was signiﬁcantly reduced in LA and PLA
in GMCT-treated compared to saline-treated groups
(Figures 5B and 5C). Rotors and wavebreaks (singu-
larity points) were counted as described previously
(15); the number of rotations, singularity points and
areas of singularity point trajectory during AF were
signiﬁcantly reduced in GMCT-treated compared to
saline-treated animals (Figures 5D to 5F). The results
observed in right atrium in vivo and ex vivo were
consistent with LA and PLA (data not shown). Alto-
gether, GMCT diminished the electrical and structural
substrates that maintain AF. In contrast to atrial ef-
fects, GMCT did not alter ventricular function or
prolong QT or QTc at ﬁnal evaluation.
At 35d-PeAF AF-induced shortening of action po-
tential duration at 90% repolarization (APD90)
measured optically was signiﬁcantly attenuated by
GMCT (Figures 6A and 6B). Conduction velocity
during pacing was identical for saline-treated and
GMCT-treated groups. Wavelength, the product of
APD90 and conduction velocity, was longer in GMCT-
treated animals in LA and right atrium at cycle
length 400 ms (184.8  6.1 mm vs. 161.4  10.6 mm,
p < 0.01; 241.3  16.7 mm vs. 194.3  14.3 mm, p <
0.01, respectively).
FIGURE 2 In Vitro Proliferation of Sheep Atrial Myoﬁbroblasts
(A) Galectin (Gal)-3 increases proliferation of sheep atrial myoﬁbroblasts; effects are blocked by GM-CT-01 (GMCT). SFM: treatment with serum
free medium, negative control; FM: treatment with full media (10% FBS), positive control. N¼ 2 to 3, n¼ 4 to 12; ***p< 0.001 versus SFM, Gal-3
(1 mg/ml), Gal-3 (10 mg/ml) þ GMCT (0.6 mg/ml); #p < 0.05, ###p < 0.001 versus Gal-3 (10 mg/ml) þ GMCT (0.125 mg/ml). (B) Transforming
growth factor beta (TGF-b1) increases proliferation of sheep atrial myoﬁbroblasts; effects are blocked by GMCT (N¼ 2 to 3, n¼ 4 to 12; *p<0.05,
#p < 0.05 vs. FM). (C) Pre-treatment with a TGF-b1 neutralizing antibody (TGF-b1 NAb, 1 ng/ml) blocks Gal-3-induced (10 mg/ml) increase
in proliferation (*p < 0.05, *** p < 0.001; N ¼ 3, n ¼ 4 to 18). (D) Gal-1 increases proliferation of sheep atrial myoﬁbroblasts; effects are not
blocked by GMCT (N ¼ 5, n ¼ 13 to 15; *p < 0.05, #p < 0.05, and ####p < 0.0001 vs. FM). N ¼ number of animals; n ¼ number of dishes.
FIGURE 3 GMCT Mitigates Structural Remodeling During AF Progression
(A) Echocardiographically obtained adjusted left atrial areas in sham (N ¼ 4), saline-treated (N ¼ 10), and GM-CT-01 (GMCT)–treated groups
(N ¼ 10). *p < 0.05 versus sham; #p < 0.05, ##p < 0.01 versus saline-treated group. One-way analysis of variance for each time point.
(B) Directly measured left atrial areas in sham (n ¼ 4), saline-treated (N ¼ 10), and GMCT-treated groups (N ¼ 10). *p < 0.05, ***p < 0.001.
(C) Single isolated left atrial cell areas. N/n ¼ 4/192 (sham), N/n ¼ 4/226 (saline), and N/n ¼ 4/234 (GMCT). N ¼ number of animals;
n ¼ number of cells. ***p < 0.001, ****p < 0.0001. 1d-AF ¼ ﬁrst 1-day-long atrial ﬁbrillation episode; 1st-AF ¼ ﬁrst atrial ﬁbrillation episode;
7d-PeAF ¼ ﬁrst continuous 7-day stretch of persistent atrial ﬁbrillation; 35d-PeAF ¼ ﬁrst continuous 35-day stretch of persistent atrial
ﬁbrillation; AF ¼ atrial ﬁbrillation; LA ¼ left atrium; PLA ¼ posterior left atrium.
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FIGURE 4 GMCT Reduces Atrial Fibrosis
(A) Serum levels of procollagen III N-terminal propeptide (P3NP) during atrial ﬁbrillation (AF) progression in saline-treated and GM-CT-
01 (GMCT)–treated (N ¼ 10, respectively) groups. Repeated measures 2-way analysis of variance with Bonferroni multiple comparisons
test, §p < 0.05 versus GMCT at 35d-PeAF, #p < 0.05 versus GMCT at baseline. (B) Protein levels of galectin (Gal)-3, Gal-1, and
transforming growth factor (TGF)-b1 in left atrium (LA) tissue samples (N ¼ 4, respectively). (C) Left: Representative picrosirius red
staining of posterior left atrium (PLA). Right: Percentage of picrosirius red showing interstitial ﬁbrosis from sham (N ¼ 4), saline-
treated (N ¼ 10), and GMCT-treated (N ¼ 10) groups. (D) (Left) Representative blots of a-smooth muscle actin (SMA) from (left lane)
sham, (middle lane) saline, and (right lane) GMCT. (Right) a-SMA in atrial homogenates in sham, saline-treated, and GMCT-treated
(N ¼ 4, respectively) groups. (E) pSmad2(Ser465/467)/Smad2/3 in LA tissue samples (N ¼ 3 to 4). *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001. 1d-AF ¼ ﬁrst 1-day-long atrial ﬁbrillation episode; 1st-AF ¼ ﬁrst atrial ﬁbrillation episode; 7d-PeAF ¼
ﬁrst continuous 7-day stretch of persistent atrial ﬁbrillation; 35d-PeAF ¼ ﬁrst continuous 35-day stretch of persistent atrial ﬁbrillation;
GAPDH ¼ glyceraldehyde 3-phosphate dehydrogenase.
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148In isolated atrial myocytes from GMCT-treated and
saline-treated animals, peak inward sodium current
and L-type calcium current were signiﬁcantly
reduced compared to sham (Supplemental Figures 3
and 4); these currents were comparable between
GMCT-treated and saline-treated groups. Changes in
sodium current and L-type calcium current wereconsistent with concomitant decreases in expression
of Nav1.5 and Cav1.2 proteins. Inward rectiﬁer potas-
sium current (IK1) increased 2-fold at negative
membrane potentials in left and right atria of
saline-treated animals, but GMCT attenuated the in-
crease (p < 0.05) (Figure 6C). Changes in IK1 were
consistent with concomitant decreases in Kir2.3
FIGURE 5 GMCT Reduces Electrical Remodeling During AF Progression
(A) Dominant frequency (DF) in LA (N ¼ 8 for saline- and GMCT-treated groups) measured in vivo (#p < 0.05 vs. saline-treated group).
(B) Representative dominant frequency (DF) maps during AF optical mapping in saline-treated (top) and GMCT-treated hearts (bottom).
(C) maximal DF, (D) number of rotations, (E) density of singularity points (SP), and (F) SP trajectory area in optical mapping for saline-treated
(N ¼ 6) and GMCT-treated hearts (N ¼ 6). *p < 0.05, **p < 0.01. Abbreviations as in Figure 4.
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149protein in LA and PLA (Figure 6D). Therefore, the
attenuation of APD shortening by GMCT during AF
can be partially attributed to mitigation of IK1 in-
crease, which is otherwise responsible for DF accel-
eration during AF progression (12). To investigate the
possibility of additional Kþ channel remodeling, IKr
block was assessed by high-throughput thallium ﬂux
assay (16); overnight treatment with GMCT did not
affect IKr (Supplemental Figure 5). Acute GMCT
treatment inhibited IKr only at 12 mg/ml, which is well
above concentrations used in in vitro experiments
(Figure 2, Supplemental Figure 1). Kv1.5 protein
(responsible for IKur) tended to decrease in LA from
GMCT-treated animals, and in 24-h cultured acute
sheep atrial myocytes, GMCT decreased IKur density
by 30% (Supplemental Figure 6). In addition, during
optical mapping of hearts from persistent AF sheep,
DPO-1 (1.0 mmol/l) an IKur blocker (17), acutely pro-
longed APD90 and decreased DF (Supplemental
Figure 7).As expected from previous work (12), ryanodine
receptor (RyR2) proteins were reduced and sodium-
calcium exchanger (NCX) proteins were increased in
AF animals (saline or GMCT) compared to sham
(Supplemental Figures 8A to 8D). SERCA, phospho-
lamban, NCX, and RyR2 proteins were similar in
saline-treated and GMCT-treated animals. Addition-
ally, caffeine-induced Ca2þ transients in isolated
sheep LA myocytes demonstrated accelerated decay
time constants (tau) in saline-treated animals
compared to sham or GMCT-treated animals, consis-
tent with changes in NCX protein levels, suggesting
that accelerated Ca2þ extrusion in AF was reversed by
GMCT-treatment. However, normalized peak Ca2þ
transient amplitudes were comparable in all groups
(Supplemental Figures 8E to 8G). Altogether, similar
Ca2þ handling properties between saline- and
GMCT-treated animals suggest that GMCT-induced
amelioration of electrical remodeling occurred inde-
pendently of altered Ca2þ handling.
FIGURE 6 GMCT Mitigates AF-Induced Shortening of APD
(A) Representative action potentials from optical mapping of saline-treated (dotted line) and GMCT-treated hearts (solid line) at 2.5 Hz pacing.
(B) Atrial optical mapping data shows cycle length (CL) dependence of action potential duration at 90% repolarization (APD90) from saline-
treated (N ¼ 6) and GMCT-treated hearts (N ¼ 6). ##p < 0.01, ###p < 0.001 versus saline-treated group. (C) Current-voltage relationships for
inward rectiﬁer potassium current (IK1). For right atrium: N/n ¼ 3/8 (sham), N/n ¼ 4/12 (saline), and N/n ¼ 3/9 (GMCT), for LA: N/n ¼ 3/9
(sham), N/n ¼ 3/13 (saline), and N/n ¼ 3/13 (GMCT). *p < 0.05 versus sham, #p < 0.05 versus GMCT. Repeated measures 2-way analysis of
variance with Bonferroni multiple comparisons test. (D) Representative Kir2.3 Western blots (left: sham, middle: saline, right: GMCT) and
quantiﬁcation of protein expression (N ¼ 4, all groups; *p < 0.05). RA ¼ right atrium; other abbreviations as in Figure 4.
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151We generated computational action potentials for
persistent AF using a human atrial action potential
model (Supplemental Figure 9) (18). Ionic changes for
modeling persistent AF were based on patch-clamp
recordings. Two-dimensional simulations showed
that sustained rotor dynamics in the saline-treated
model exhibited higher rotational frequency (9.8 Hz)
than the GMCT-treated model (7.8 Hz).
AF INDUCIBILITY, BURDEN, AND SPONTANEOUS
CARDIOVERSION IN SHEEP. GMCT-treated animals
spent longer time in sinus rhythm and had more
frequent spontaneous AF terminations than
saline-treated animals (Figures 7A and 7B). AF induc-
ibility index (inverse of pacing attempts to reinduce
AF) after 7d-PeAF was signiﬁcantly reduced in
GMCT-treated compared to saline-treated animals
(Figure 7C), suggesting GMCT-treated animals were
less vulnerable to AF. GMCT signiﬁcantly reduced AF
burden, particularly during time points associated
with paroxysmal AF (Figure 7D). At later times and
after more sustained AF episodes, AF burden, and
inducibility index converged.
DISCUSSION
Here we demonstrate for the ﬁrst time that Gal-3
mediates sustained AF-induced atrial structural and
electrical remodeling and contributes to AF perpetu-
ation. In patients, intracardiac serum Gal-3 levels
were greater in persistent than paroxysmal AF and
the Gal-3 level was an independent predictor of AF
recurrences after a single ablation procedure. In a
sheep model, the Gal-3 inhibitor GMCT reduced atrial
ﬁbroblast proliferation in vitro. In vivo, GMCT miti-
gated atrial dilation, myocyte hypertrophy, ﬁbrosis,
and the expected increase in DF during transition to
persistent AF. Ex vivo, GMCT-treated hearts had
longer action potential durations, and fewer rotors
and wavebreaks during AF than control. GMCT
increased the number of spontaneous AF termina-
tions and reduced overall AF burden.
A recent study in patients suggested that serum
Gal-3 from peripheral blood was not associated with
sinus rhythm maintenance and questioned its use-
fulness in predicting rhythm outcome of catheter
ablation (11). In sharp contrast, our results derived
from intracardiac measurements of Gal-3 levels from
the CS and LA are signiﬁcantly higher in patients with
persistent than paroxysmal AF, in agreement with
another study showing that peripheral plasma Gal-3
predicted clinical outcomes after catheter ablation
(10). Moreover, Gal-3 levels correlated positively with
left atrial volume index and inversely with AF cycle
length (Figure 1), supporting a role for proﬁbroticmolecules in the progression of structural and elec-
trical remodeling in patients with persistent AF.
These data are consistent with previous clinical
ﬁndings showing that serum Gal-3 levels are corre-
lated with LA-structural remodeling (19). Atrial size is
an important determinant of AF (20) and larger atria
have a higher probability for initiation and mainte-
nance of rotor-driven ﬁbrillatory activity (21). In-
ﬂammatory markers have been suggested to play a
role in AF perpetuation (22). However, inﬂammatory
inﬁltrates need not be present in the atria of patients
with persistent AF (23), which is consistent with our
results showing no changes in CRP or BNP (Figure 1).
Gal-3 has been shown to play a key role in human
diseases associated with ﬁbrosis, including cancer,
cirrhosis (24), renal failure (3), lung disease (8), and
heart failure (25). However, while there is an urgent
need for development of inhibitors that speciﬁcally
target Gal-3, there is currently no commercially
available anti-Gal-3 therapeutic reagent (26).
Recently Gal-3 inhibition with GMCT signiﬁcantly
reduced ﬁbrosis and reversed cirrhosis, and reduced
Gal-3 expressing portal and septal macrophages in a
rat model of liver disease (27). In our sheep model,
GMCT mitigated both electrical and structural
remodeling during AF progression. Myocyte hyper-
trophy was also diminished, possibly due to the in-
hibition of TGF-b1, a key mediator of angiotensin II–
induced cardiac ﬁbrosis and hypertrophy (28). Gal-3 is
known to retain TGF-b receptors on the myoﬁbroblast
cell membrane by binding to the receptor’s poly N-
acetyl lactosamine residues, which promotes
signaling through Smad and Akt pathways (8). By
binding to the CRD of Gal-3 (4), GMCT may have
reduced activation of the TGF-b/Smad pathway in
myocytes and myoﬁbroblasts, leading to reduction of
cardiac ﬁbrosis (29). Increased a-SMA protein in the
PLA and LA from saline-treated animals may reﬂect
progressive myoﬁbroblast activation evoked by
tachypacing that contributed to ﬁbrosis via autocrine
and paracrine mechanisms (30). Thus, lower a-SMA
expression in GMCT-treated animals likely reﬂects
attenuated myoﬁbroblast activation via inhibition of
TGF-b1/Smad pathway (31). Altogether, these ﬁndings
suggest a mechanistic involvement of Gal-3 via TGF-b
mediated pathways in the pathophysiology of atrial
ﬁbrosis. Moreover, the results suggest that GMCT in-
terferes with the association between Gal-3 and the
TGF-b receptor during AF, which inhibits TGF-b1
mediated signaling and reduces myoﬁbroblast acti-
vation leading to prevention of pathological collagen
deposition.
Gal-1 increases cardiac myoﬁbroblast prolifera-
tion (Figure 2D), consistent with known properties
FIGURE 7 GMCT Reduces AF Inducibility and Promotes AF Termination
(A) Kaplan-Meier plot for freedom from 35d-PeAF in saline-treated (N ¼ 10) and GMCT-
treated groups (N ¼ 10). p ¼ 0.3254. (B) Number of AF terminations after 7d-PeAF for
saline-treated (N/n ¼ 3/29) and GMCT-treated groups (N/n ¼ 7/82). (C) Left: AF induc-
ibility index for saline-treated (N ¼ 10) and GMCT-treated groups (N ¼ 10) throughout AF
progression. #p < 0.0001 versus saline-treated animals. (Right) AF inducibility index after
7d-PeAF in GMCT-treated (N/n ¼ 7/77) and saline-treated (N/n ¼ 3/32) animals. (D) (Left)
AF burden in GMCT-treated (N ¼ 10) and saline-treated (N ¼ 10) animals. (Right) Overall
AF burden in GMCT-treated (N/n ¼ 10/199) and saline-treated (N/n ¼ 10/187) animals.
N ¼ number of animals; n ¼ number of AF episodes. Statistics: (A) Gehan-Breslow-
Wilcoxon test, (C, D left)Mann-Whitney U test at each individual time point, (B, C, D right)
Mann-Whitney U test. *p < 0.05, **p < 0.01. Abbreviations as in Figure 4.
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152of Gal-1 inducing dermal- and gingival-derived
myoﬁbroblast activation, migration, and prolifera-
tion (32). However, GMCT did not inhibit the effect
of Gal-1 at the same dose which completely
inhibited Gal-3 proliferation, suggesting that GMCT
has higher afﬁnity and more speciﬁcity to Gal-3
than Gal-1. Moreover, Gal-1 protein in AF sheep
tissue is reduced compared to sham (Figure 4B),
suggesting that Gal-1 may not be a key regulator of
AF. Altogether, these data suggest that the beneﬁ-
cial effects of GMCT are due to Gal-3 inhibition and
not Gal-1.
AF progression was characterized by continuously
increasing DF until AF became persistent, similar to
our previous report (12). Notably, although DF
increased progressively as a consequence of electrical
remodeling, GMCT reduced DF acceleration, resulting
in a lower terminal maximal DF than saline-treated
animals at similar time points. Optical mapping
showed fewer rotors and wavebreaks in GMCT-
treated hearts, likely due to prolonged APDs and
refractory periods, as well as a less dense ﬁbrotic
substrate where rotors could anchor to maintain AF.
Atrial ﬁbroblast proliferation might be responsible for
complex fractionated atrial electrograms during
persistent/permanent AF (33). This is consistent with
our observation of fewer spiral wave breaks in GMCT-
treated hearts.
Increased IK1 is a major factor in AF maintenance
(12,34). Treatment with GMCT attenuated IK1 and IKur
remodeling which likely reduced APD prolongation,
slowed DF and contributing to fewer rotors than
saline-treated animals. Numerical simulations pre-
dicted that the effects of GMCT on IKur and IK1 should
mitigate AF-induced APD shortening and slow rotor
frequency (Supplemental Figure 9). This provides an
ionic mechanism for the putative effects of GMCT on
DF reduction.
Changes in calcium handling proteins associated
with AF were consistent with previous ﬁndings
(12,35,36). In rabbits, 5-day-sustained high atrial
activation rate induced Ca2þ signaling silencing
through a failure of subcellular propagated Ca2þ
release (35). In 1-year persistent AF sheep, although
NCX was increased in LA, both total RyR2 and phos-
phorylated RyR2 proteins were decreased, and the
ratio of phosphorylated RyR2 to total RyR2 phos-
phorylation was unaffected (12). CaMKII appeared to
facilitate catecholamine-evoked arrhythmias in atrial
tissue of patients with sinus rhythm, but it failed to
elicit arrhythmias of patients with chronic AF (36). In
the current study, we can safely conclude that
attenuation of electrical remodeling by GMCT was not
due to recovery of Ca2þ-handling dysfunction, since
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Gal-3 represents
a common upstream link for both structural and electrical
remodeling and a mediator in transition to persistent AF through
its effects promoting gene transcription via cytokine mediated
signaling pathways.
TRANSLATIONAL OUTLOOK: Should that prove to be true in
human AF, then demonstration that one of several types of Gal-3
inhibitors halts AF progression might lead to the ﬁrst generation
of disease-modifying therapies aimed at preventing AF perpet-
uation and improving AF ablation outcomes.
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153GMCT did not rescue AF-remodeled SERCA, NCX, or
RyR2.
In addition to decreasing AF inducibility, GMCT
signiﬁcantly increased the probability of spontaneous
cardioversion to sinus rhythm during persistent AF,
which may be explained by a combination of effects:
ﬁrst, GMCT ameliorated atrial dilation and ﬁbrosis,
both of which are believed to contribute to a substrate
for reentry; and second, GMCT signiﬁcantly mitigated
Kþ channel remodeling, APD shortening and DF in-
crease, all of which mark the progression toward
persistent AF (12). However, we cannot exclude the
possibility that GMCT ameliorated electrical remod-
eling through other means that we have not explored.
The pleiotropic actions of Gal-3 suggest possible roles
in cardiomyocytes, including direct modulation of
cardiac ion channel function. Gal-3 interacts with
beta-galactoside residues of cell surface and matrix
glycoproteins through its carbohydrate-binding
domain (37). Both voltage-gated Naþ and some Kþ
channels are glycoproteins that contain large
amounts of post-translationally attached sialic acids
(38). Glycosylation is important for membrane pro-
tein folding, cell surface targeting, and function (39).
Evidence indicates that in kidney, galectin–N-glycan
interaction may contribute to preventing internali-
zation of both inward rectiﬁer (ROMK1) and transient
receptor potential cation channels (40). Potassium
ion channels, Kir2.3 and Kv1.5, are thought to be
internalized by clathrin dependent pathways via
endocytosis (41,42). Similar to TGF-b receptors, Gal-3
might act by preventing internalization of such pro-
teins (43). Gal-3 oligomers might bind to and retain
Kir2.3 and Kv1.5 channels of atrial myocytes, giving
rise to APD shortening and DF increase. GMCT may
act by inhibiting binding of Gal-3 to Kir2.3 and Kv1.5
channels in atrial myocytes, thus decreasing current
density and mitigating APD shortening and DF in-
crease during AF progression. Further studies are
required to elucidate better the speciﬁc molecular
mechanisms in this process.
STUDY LIMITATIONS. We used a tachypacing
induced persistent AF sheep model in which
continuous sinus rhythm was not permitted, because
pacing resumed immediately after AF spontaneous
conversion. Thus, it is unknown whether GMCT af-
fects AF induction by modulating pacing-induced
focal atrial ectopic depolarizations or PV arrhyth-
mogenesis. Although the ﬁndings from the experi-
mental model of AF correlate well with the clinical
study, the mechanisms of AF in pacing-induced AF
sheep and in humans with AF may have nuanced
differences. The intense burst pacing in the sheepmodel may be more aggressive than intrinsic
AF-initiating events during the natural progression
of paroxysmal to persistent AF in humans, where
instances of AF reinitiation may be much more
infrequent. Thus, Gal-3 inhibition only delayed
development of AF and did not signiﬁcantly improve
long-term outcomes in the present study. In the
human condition where durations between AF par-
oxysms may last weeks or months, delayed progres-
sion of AF may have greater impact on reducing AF
burden than in our model. Last, Gal-3 is secreted by
macrophages, kidneys, and vasculature (3). Even
though blood samples were obtained from CS and LA
to assess cardiac-derived Gal-3, it could reﬂect
changes in Gal-3 production in other organs.
CONCLUSIONS
Inhibiting Gal-3 during AF progression might be use-
ful as an adjuvant treatment to improve outcomes of
catheter ablation for persistent AF. Gal-3 inhibition
may be a potential new upstream therapy for the
prevention of AF progression.
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